David C. Aron, MD, MS; Paul R. Conlin, MD; Leonard Pogach, MD, MBA
Disclaimer: The views expressed here are not to be construed as those of the U.S. Department of Veterans Affairs or the U.S. Department of Defense.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-1342.
Corresponding Author: Leonard Pogach, MD, MBA, Veterans Affairs Central Office, Office of Specialty Care (P11), 810 Vermont Avenue, Washington, DC 20420; e-mail, Leonard.Pogach@va.gov.
Current Author Addresses: Dr. Aron: Director, Clinical Program Research and Evaluation, Louis Stokes Cleveland VA Medical Center Administrative, Building EUL 5M677, 10701 East Boulevard, Cleveland, OH 44106.
Dr. Conlin: Chief, Medical Service, VA Boston Healthcare System, 1400 Veterans of Foreign Wars Parkway, West Roxbury, MA 02132.
Dr. Pogach: Veterans Affairs Central Office, Office of Specialty Care (P11), 810 Vermont Avenue, Washington, DC 20420.
Author Contributions: Conception and design: L. Pogach.
Drafting of the article: L. Pogach.
Critical revision of the article for important intellectual content: P.R. Conlin, L. Pogach.
Final approval of the article: D.C. Aron, P.R. Conlin, L. Pogach.
Aron DC, Conlin PR, Pogach L. Brief Commentary: The Glycemic Target Guideline Controversy: Same Evidence, Different Perspectives, and a Proposal for Common Ground. Ann Intern Med. ;169:248–249. doi: 10.7326/M18-1342
Download citation file:
© 2019
Published: Ann Intern Med. 2018;169(4):248-249.
DOI: 10.7326/M18-1342
Published at www.annals.org on 26 June 2018
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by: